PDF DatasheetHuman Anti-EMI1 Antibody Product Attributes
EMI1 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-FBXO5 antibody staining is expected to be primarily localized to the nucleoplasm.
Observed Antibody Staining Data By Tissue Type:
Variations in EMI1 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the tubules in kidney and Purkinje cells in the cerebellum. More moderate antibody staining intensity was present in cells in the tubules in kidney and Purkinje cells in the cerebellum. Low, but measureable presence of EMI1 could be seen inadipocytes in mesenchymal tissue, bile duct cells in the liver, cells in the granular layer in cerebellum, cells in the red pulp in spleen, cells in the white pulp in spleen, decidual cells in the placenta, endothelial cells in the cerebral cortex, exocrine glandular cells in the pancreas, follicle cells in the ovary, glandular cells in the appendix, cervix, uterine, fallopian tube, parathyroid gland, prostate, salivary gland, seminal vesicle, small intestine, stomach and thyroid gland, glial cells in the caudate nucleus and hippocampus, hepatocytes in liver, islets of Langerhans in pancreas, lymphoid tissue in appendix, myocytes in heart muscle, neuronal cells in the hippocampus, neuropil in cerebral cortex, ovarian stroma cells in the ovary, squamous epithelial cells in the cervix and uterine. We were unable to detect EMI1 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of EMI1 expression as measured by anti-EMI1 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | + | ++ | ++ | + | ++ | – | + | + | + | ++ | ++ | + | ++ | + | + | – | ++ | ++ |
| FBXO5 Variability | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | +++ | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ |
| EMI1 General Information | |
|---|---|
| Alternate Names | |
| F-box only protein 5, FBXO5 | |
| Molecular Weight | |
| 56kDa | |
| Chromosomal Location | |
| 6q25.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | FBXO5 |
| Entrez Gene ID | 26271 |
| Ensemble Gene ID | ENSG00000112029 |
| RefSeq Protein Accession(s) | NP_036309, NP_001135994 |
| RefSeq mRNA Accession(s) | NM_012177, NM_001142522 |
| RefSeq Genomic Accession(s) | NC_000006, NC_018917 |
| UniProt ID(s) | Q9UKT4 |
| UniGene ID(s) | Q9UKT4 |
| HGNC ID(s) | 13584 |
| Cosmic ID(s) | FBXO5 |
| KEGG Gene ID(s) | hsa:26271 |
| PharmGKB ID(s) | PA28045 |
| General Description of EMI1. | |
| It recognizes a 56kDa protein, which is identified as Early Mitotic Inhibitor-1 (EMI1). It regulates mitosis by inhibiting the anaphase promoting complex/cyclosome (APC). Emi1 is a conserved F box protein containing a zinc-binding region essential for APC inhibition. The Emi1 protein functions to promote cyclin A accumulation, S phase entry in somatic cells by inhibiting the APC complex. At the G1-S transition, Emi1 is transcriptionally induced by the E2F transcription factor. Emi1 overexpression accelerates S-phase entry, can override a G1 block caused by overexpression of Cdh1 or the E2F-inhibitor p105 retinoblastoma protein (pRb). Depleting cells of Emi1 through RNA interference prevents accumulation of cyclin A, inhibits S phase entry. | |
There are no reviews yet.